Intended Use
For In Vitro Diagnostic Use
Summary and Explanation
Myeloid cell Nuclear Differentiation Antigen (MNDA) is present in granulocytes and monocytes (myeloid and B cells), found in the marginal zones of germinal centers in tonsil, lymph node, spleen. MNDA is a highly basic protein from 1q22, and is part of the family of nuclear proteins expressed in reaction to interferons. MNDA contains a Pyrin ‘death domain’ used in self-association and is suggested to induce or help prevent different programmed cell death pathways in hematopoietic cells.
MNDA antibody expression is studied mainly in leukemias and lymphomas. MNDA antibody is a marker to distinguish Nodal Marginal Zone Lymphoma from Follicular Lymphoma, and has been shown to be downregulated in Myelodysplastic Syndrome, a precursor for Leukemia. MNDA overexpression in Osteosarcoma induces apoptosis and protects patients from metastasis, and expression in Chronic Lymphocytic Leukemia indicates the degradation of anti-apoptotic mRNA, allowing cells suffering genotoxic stress to undergo apoptosis.
Synonyms: MNDA, anti-mnda, Myeloid cell Nuclear Differentiation Antigen, anti-Myeloid cell Nuclear Differentiation Antigen